Cytochrome P4502C9 genotype: Impact on celecoxib safety and pharmacokinetics in a pediatric patient

被引：28
|
作者：
Stempak, D
Bukaveckas, BL
Linder, M
Koren, G
Baruchel, S
机构：
[1] Hosp Sick Children, Div Hematol Oncol, New Agent & Innovat Therapy Program, Toronto, ON M5G 1X8, Canada
[2] Hosp Sick Children, Div Clin Pharmacol & Toxicol, New Agent & Innovat Therapy Program, Toronto, ON M5G 1X8, Canada
[3] Univ Louisville, Dept Pathol & Lab Med, Louisville, KY 40292 USA
[4] Hosp Sick Children, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada
[5] Hosp Sick Children, Div Hematol Oncol, New Agent & Innovat Therapy Program, Toronto, ON M5G 1X8, Canada
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2005年 / 78卷 / 03期
关键词：
D O I：
10.1016/j.clpt.2005.06.005
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：309 / 310
页数：2
相关论文
共 50 条
  • [1] Lornoxicam pharmacokinetics in relation to cytochrome P4502C9 genotype
    Zhang, YF
    Zhong, DF
    Si, DY
    Guo, YJ
    Chen, XY
    Zhou, H
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (01) : 14 - 17
  • [2] Acenocoumarol pharmacokinetics in relation to cytochrome P4502C9 genotype
    Thijssen, HHW
    Ritzen, B
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (01) : 61 - 68
  • [3] Oxidation of celecoxib by polymorphic cytochrome P4502C9 and alcohol dehydrogenase
    Sandberg, M
    Yasar, Ü
    Strömberg, P
    Höög, JO
    Eliasson, E
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (04) : 423 - 429
  • [4] Pharmacokinetics of glimepiride and cytochrome P4502C9 genetic polymorphisms
    Wang, R
    Chen, K
    Wen, SY
    Li, J
    Wang, SQ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (01) : 90 - 92
  • [5] Influence of age and cytochrome P4502C9 genotype on the steady-state disposition of diclofenac and celecoxib
    Brenner, SS
    Herrlinger, C
    Dilger, K
    Mürdter, TE
    Hofmann, U
    Marx, C
    Klotz, U
    CLINICAL PHARMACOKINETICS, 2003, 42 (03) : 283 - 292
  • [6] Is cytochrome P4502C9 genotype associated with NSAID gastric ulceration?
    Martin, JH
    Begg, EJ
    Kennedy, MA
    Roberts, R
    Barclay, ML
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (06) : 627 - 630
  • [7] Cytochrome P450 2C9 genotype: Impact on celecoxib safety and pharmacokinetics in a pediatric patient (vol 78, pg 309, 2005)
    Stempak, D.
    Bukaveckas, B. L.
    Linder, M.
    Koren, G.
    Baruchel, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (06) : 690 - 690
  • [8] Warfarin dosing and cytochrome P4502C9 polymorphisms
    Joffe, HV
    Xu, RL
    Johnson, FB
    Longtine, J
    Kucher, N
    Goldhaber, SZ
    THROMBOSIS AND HAEMOSTASIS, 2004, 91 (06) : 1123 - 1128
  • [9] Warfarin and cytochrome P4502C9 genotype: possible ethnic variation in warfarin sensitivity
    Kealey, Canel
    Chen, Zhen
    Christie, Jason
    Thorn, Caroline F.
    Whitehead, Alexander S.
    Price, Maureen
    Samaha, Frederick F.
    Kimmel, Stephen E.
    PHARMACOGENOMICS, 2007, 8 (03) : 217 - 225
  • [10] Allelic and functional variability of cytochrome P4502C9
    Bhasker, CR
    Miners, JO
    Coulter, S
    Birkett, DJ
    PHARMACOGENETICS, 1997, 7 (01): : 51 - 58
12345